Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

耐受性 安慰剂 医学 人口 锥体外系症状 精神分裂症(面向对象编程) 临床终点 随机对照试验 不利影响 内科学 精神科 抗精神病药 病理 环境卫生 替代医学
作者
John H. Krystal,John M. Kane,Christoph U. Correll,David Walling,Matthew Leoni,Sridhar Duvvuri,Shrinal Patel,Ih Chang,Philip Iredale,Lillian Frohlich,Stacey Versavel,Pamela Perry,Raymond Sanchez,John J. Renger
出处
期刊:The Lancet [Elsevier]
卷期号:400 (10369): 2210-2220 被引量:31
标识
DOI:10.1016/s0140-6736(22)01990-0
摘要

Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator in development for the treatment of schizophrenia. We aimed to evaluate the safety and tolerability of multiple ascending doses of emraclidine in patients with schizophrenia.We conducted a two-part, randomised, phase 1b trial in the USA. Eligible participants were aged 18-50 years (part A) or 18-55 years (part B) with a primary diagnosis of schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders 5th edition, as confirmed by the Mini International Neuropsychiatric Interview, and extrapyramidal symptom assessments indicating normal to mild symptoms at screening. Part A evaluated the safety and tolerability of emraclidine in five cohorts of participants with stable schizophrenia who received ascending oral doses of emraclidine 5-40 mg (40 mg was administered as 20 mg twice daily) or placebo at a single US site. Part B was a double-blind, randomised, placebo-controlled study that enrolled adults with acute schizophrenia across five US sites; participants were randomly assigned (1:1:1) to receive emraclidine 30 mg once daily, emraclidine 20 mg twice daily, or placebo for 6 weeks (doses established in part A). The primary endpoint was safety and tolerability, assessed in the safety population (participants who received at least one dose of emraclidine or placebo). This trial is now complete and is registered with ClinicalTrials.gov, NCT04136873.Between Sept 23, 2019, and Sept 17, 2020, 118 patients were assessed for eligibility and 49 were randomly assigned across five cohorts in part A. 44 participants completed the study, with 36 participants receiving emraclidine and eight receiving placebo. The two highest doses tested were selected for part B. Between Oct 12, 2020, and May 7, 2021, 148 patients were assessed for eligibility and 81 were randomly assigned to emraclidine 30 mg once daily (n=27), emraclidine 20 mg twice daily (n=27), or placebo (n=27) in part B. Incidence of adverse events (14 [52%] of 27 participants in the emraclidine 30 mg once daily group, 15 [56%] of 27 in the emraclidine 20 mg twice daily group, and 14 [52%] of 27 in the placebo group), clinical assessments, and weight changes were similar across groups. The most common adverse event was headache (15 [28%] of 54 participants in the emraclidine groups, seven [26%] of 27 in the placebo group). Modest, transient increases in blood pressure and heart rate in emraclidine groups observed at treatment initiation diminished over time and were not considered clinically meaningful by week 6.These data support further investigation of emraclidine as a once-daily treatment for schizophrenia without need for titration and with a potentially favourable side-effect profile.Cerevel Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小武哥完成签到 ,获得积分10
2秒前
5秒前
6秒前
追寻发布了新的文献求助10
13秒前
yahonyoyoyo发布了新的文献求助10
18秒前
21秒前
彩色布条完成签到,获得积分10
22秒前
22秒前
稍稍完成签到,获得积分10
23秒前
赘婿应助科研通管家采纳,获得10
24秒前
今后应助科研通管家采纳,获得10
25秒前
天天快乐应助科研通管家采纳,获得10
25秒前
汉堡包应助科研通管家采纳,获得10
25秒前
25秒前
25秒前
觀海聴濤发布了新的文献求助10
28秒前
小房子发布了新的文献求助10
29秒前
稳重书双发布了新的文献求助10
29秒前
33秒前
34秒前
少年旭发布了新的文献求助10
35秒前
林嘉发布了新的文献求助10
36秒前
飘逸妙芙发布了新的文献求助10
38秒前
脑洞疼应助drtianyunhong采纳,获得10
39秒前
阮煜城完成签到,获得积分10
41秒前
42秒前
43秒前
JokerJie发布了新的文献求助10
45秒前
46秒前
贾静雯应助雪山飞狐采纳,获得10
46秒前
GalaxyLee应助zuly采纳,获得10
47秒前
47秒前
PangSir完成签到,获得积分10
49秒前
yuanyuan发布了新的文献求助10
50秒前
晚凝发布了新的文献求助30
50秒前
勤恳发布了新的文献求助10
50秒前
orixero应助以旋采纳,获得10
51秒前
53秒前
自由完成签到 ,获得积分10
53秒前
田様应助yishan采纳,获得10
56秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Chinese-English Translation Lexicon Version 3.0 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 400
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 400
薩提亞模式團體方案對青年情侶輔導效果之研究 400
3X3 Basketball: Everything You Need to Know 310
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2386515
求助须知:如何正确求助?哪些是违规求助? 2092963
关于积分的说明 5266585
捐赠科研通 1819823
什么是DOI,文献DOI怎么找? 907766
版权声明 559181
科研通“疑难数据库(出版商)”最低求助积分说明 484897